[go: up one dir, main page]

ZA200506906B - Biaryl substituted triazoles as sodium channel blockers - Google Patents

Biaryl substituted triazoles as sodium channel blockers

Info

Publication number
ZA200506906B
ZA200506906B ZA200506906A ZA200506906A ZA200506906B ZA 200506906 B ZA200506906 B ZA 200506906B ZA 200506906 A ZA200506906 A ZA 200506906A ZA 200506906 A ZA200506906 A ZA 200506906A ZA 200506906 B ZA200506906 B ZA 200506906B
Authority
ZA
South Africa
Prior art keywords
sodium channel
channel blockers
substituted triazoles
biaryl substituted
biaryl
Prior art date
Application number
ZA200506906A
Other languages
English (en)
Inventor
Prasun K Chakravarty
Palucki Brenda
William H Parson
James P Carey
Michael H Kress
Michael H Fisher
Min K Park
Zhou Bishan
Douglas E Frantz
Weaver Damian
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA200506906B publication Critical patent/ZA200506906B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200506906A 2003-03-18 2005-08-29 Biaryl substituted triazoles as sodium channel blockers ZA200506906B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
ZA200506906B true ZA200506906B (en) 2007-02-28

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200506906A ZA200506906B (en) 2003-03-18 2005-08-29 Biaryl substituted triazoles as sodium channel blockers

Country Status (34)

Country Link
US (2) US7326726B2 (zh)
EP (1) EP1606269B1 (zh)
JP (1) JP4482554B2 (zh)
KR (1) KR100737721B1 (zh)
CN (2) CN101289428A (zh)
AR (1) AR044503A1 (zh)
AT (1) ATE412639T1 (zh)
AU (1) AU2004221885C1 (zh)
BR (1) BRPI0408407A (zh)
CA (1) CA2519252C (zh)
CL (1) CL2004000551A1 (zh)
CY (1) CY1108720T1 (zh)
DE (1) DE602004017438D1 (zh)
DK (1) DK1606269T3 (zh)
EC (1) ECSP056018A (zh)
EG (1) EG25994A (zh)
ES (1) ES2314387T3 (zh)
HR (1) HRP20050816A2 (zh)
IS (1) IS8001A (zh)
JO (1) JO2480B1 (zh)
MA (1) MA27665A1 (zh)
MX (1) MXPA05009847A (zh)
MY (1) MY142651A (zh)
NO (1) NO20054775L (zh)
NZ (1) NZ542205A (zh)
PE (1) PE20041066A1 (zh)
PL (1) PL1606269T3 (zh)
PT (1) PT1606269E (zh)
RU (1) RU2356897C2 (zh)
SI (1) SI1606269T1 (zh)
TW (1) TWI337605B (zh)
UA (1) UA81660C2 (zh)
WO (2) WO2004083190A1 (zh)
ZA (1) ZA200506906B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524803T3 (es) 2002-12-19 2014-12-12 The Scripps Research Institute Composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento anómalo de la transtiretina
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
KR20060123739A (ko) * 2003-11-10 2006-12-04 머크 앤드 캄파니 인코포레이티드 나트륨 채널 차단제로서의 치환된 트리아졸
US20050261365A1 (en) 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
DE602006015215D1 (de) 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
JP2010516731A (ja) * 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5523839B2 (ja) 2007-02-08 2014-06-18 シンタ ファーマシューティカルズ コーポレーション 癌などの増殖障害の治療に有用なトリアゾール化合物
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (zh) 2011-07-01 2018-04-28
KR20140054231A (ko) 2011-09-16 2014-05-08 화이자 인코포레이티드 트랜스티레틴 해리 억제제의 고체 형태
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EP2967073B9 (en) 2013-03-15 2019-04-10 Bristol-Myers Squibb Company Lxr modulators
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
EP3762367A1 (en) * 2018-03-09 2021-01-13 PI Industries Ltd. Heterocyclic compounds as fungicides
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (zh) 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
BR0009322A (pt) * 1999-03-26 2002-04-30 Euro Celtique Sa Pirazóis, imidazóis, oxazóis, tiazóis e pirróis substituìdos com arila e o uso dos mesmos
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1390353A1 (en) * 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
HRP20050001A2 (en) * 2002-07-09 2005-08-31 Bristol-Myers Squibb Company A Delaware (Usa) Corp Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
KR20060123739A (ko) * 2003-11-10 2006-12-04 머크 앤드 캄파니 인코포레이티드 나트륨 채널 차단제로서의 치환된 트리아졸

Also Published As

Publication number Publication date
AU2004221885A1 (en) 2004-09-30
CN1788002A (zh) 2006-06-14
EP1606269B1 (en) 2008-10-29
US20050119261A1 (en) 2005-06-02
RU2356897C2 (ru) 2009-05-27
EG25994A (en) 2012-11-28
NZ542205A (en) 2008-11-28
PT1606269E (pt) 2008-12-16
ES2314387T3 (es) 2009-03-16
WO2004083190A1 (en) 2004-09-30
CN101289428A (zh) 2008-10-22
CY1108720T1 (el) 2013-09-04
IS8001A (is) 2005-08-29
CA2519252C (en) 2008-11-18
ECSP056018A (es) 2006-01-27
NO20054775L (no) 2005-12-16
MY142651A (en) 2010-12-15
AR044503A1 (es) 2005-09-14
ATE412639T1 (de) 2008-11-15
CL2004000551A1 (es) 2005-01-21
AU2004221885B2 (en) 2010-04-22
NO20054775D0 (no) 2005-10-17
DE602004017438D1 (de) 2008-12-11
HRP20050816A2 (hr) 2006-04-30
RU2005132168A (ru) 2006-04-27
KR100737721B1 (ko) 2007-07-11
US20080171777A1 (en) 2008-07-17
MXPA05009847A (es) 2005-12-05
US7572822B2 (en) 2009-08-11
JO2480B1 (en) 2009-01-20
BRPI0408407A (pt) 2006-03-21
PE20041066A1 (es) 2005-01-22
TWI337605B (en) 2011-02-21
UA81660C2 (ru) 2008-01-25
TW200505876A (en) 2005-02-16
SI1606269T1 (sl) 2009-02-28
JP4482554B2 (ja) 2010-06-16
AU2004221885C1 (en) 2010-09-23
DK1606269T3 (da) 2009-02-09
PL1606269T3 (pl) 2009-04-30
KR20050109583A (ko) 2005-11-21
JP2006520782A (ja) 2006-09-14
CA2519252A1 (en) 2004-09-30
WO2004083189A1 (en) 2004-09-30
EP1606269A1 (en) 2005-12-21
MA27665A1 (fr) 2005-12-01
US7326726B2 (en) 2008-02-05

Similar Documents

Publication Publication Date Title
EG25994A (en) Biaryl substituted triazoles as sodium channel blockers
EP1670475A4 (en) ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
EP1670474A4 (en) BLOCKERS OF THE PYRAZINOYL-GUANIDINE SODIUM CHANNEL
DK1663235T3 (da) Beskyttede pyrazinoylguanidin-natriumkanal-blokkere
AU2003248122A8 (en) Sodium channel inhibitor
EP1542686A4 (en) ARYL-SUBSTITUTED HYDANTOIN COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS
EP1534259A4 (en) SULFONAMIDES AS POTASSIUM CHANNEL BLOCKING AGENTS
GB0304424D0 (en) Novel compounds
EP1596860A4 (en) NEW CONNECTIONS
TWI319322B (en) Frozen-dried preperation containing prostaglandin
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
SI1485359T1 (sl) Blokatorji natrijevega kanala
GB0323098D0 (en) Improvements relating to communications
HK1088533A (zh) 脂肪族吡嗪並基胍鈉通道阻斷劑
GB0216212D0 (en) Sodium channel inhibitors
GB0406004D0 (en) Sodium channels
GB0406001D0 (en) Sodium channels
GB0406002D0 (en) Sodium channels
GB0406006D0 (en) Sodium channels
GB0224206D0 (en) Improvements relating to communications
GB0301955D0 (en) Novel compounds
GB0302988D0 (en) Novel compounds
GB0301589D0 (en) Novel compounds
GB0301591D0 (en) Novel compounds